Metaplastic breast carcinomas (MBCs) are basal-like tumors that frequently express epidermal growth factor receptor (EGFR) via an unknown underlying genetic mechanism. In this study, the EGFR/CEP7 gene copy number in 17 MBCs with chondroid, squamous, and spindle-cell differentiation showing EGFR expression by immunohistochemistry was analyzed using fluorescence in situ hybridization. All cases had a balanced EGFR/CEP7 ratio. EGFR gene amplification was not observed in any case. Monosomy was found in 25% and polysomy in 12.5% of carcinomas with chondroid differentiation. All spindle-cell carcinomas and 50% of squamous carcinomas showed trisomy. Comparison with CEP7 copy number revealed aneusomy of chromosome 7, as opposed to increases or decreases specific to the EGFR gene or 7p. Although no direct correlation between EGFR expression by immunohistochemistry and aneusomy was observed, cases with a score of 3+ showed a higher frequency of EGFR gene copy gain. In the absence of EGFR amplification, chromosome 7 aneusomy might be a useful criterion for the determination of potential candidates for EGFR tyrosine kinase inhibitor clinical trials.
Ellis IO, Schnitt SJ, Sastre-Garau X., et al. Invasive breast carcinoma. Metaplastic carcinoma. In: Tavassoli FA, Devilee P, eds. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. 1st ed. World Health Organization Classification of Tumours. Lyon, France: IARC Press; 2003:37-41.
2.
Tavassoli FAMetaplastic carcinoma. In: Tavassoli FA, ed. Pathology of the Breast. 2nd ed. Stamford, CT: Appleton & Lange; 1999:481-504.
3.
Huvos AG, Lucas JC Jr, Foote FW Jr.Metaplastic carcinoma. Rare form of mammary cancer. N Y State J Med.1973; 73:1078-1082.
4.
Gwin K., Wheeler D., Bossuyt V., Tavassoli FABreast carcinoma with chondroid differentiation: a clinicopathologic study of 21 triple negative (ER-, PR-, Her2/neu-) cases [published online ahead of print March 11, 2009]. Int J Surg Pathol. doi:10.1177/1066896909332732.
5.
Barnes PJ, Boutilier R., Chiasson D., Rayson D.Metaplastic breast carcinoma: clinical-pathologic characteristics and HER2/ neu expression. Breast Cancer Res Treat. 2005 ;91:173-178.
6.
Bossuyt V., Fadare O., Martel M., et al. Remarkably high frequency of EGFR expression in breast carcinomas with squamous differentiation. Int J Surg Pathol. 2005;13:319-327.
7.
Leibl S., Moinfar F.Metaplastic breast carcinomas are negative for Her-2 but frequently express EGFR (Her-1): potential relevance to adjuvant treatment with EGFR tyrosine kinase inhibitors? J Clin Pathol. 2005;58:700-704.
8.
Reis-Filho JS , Milanezi F., Steele D., et al. Metaplastic breast carcinomas are basal-like tumours. Histopathology. 2006;49: 10-21.
9.
Gilbert JA, Goetz MP, Reynolds CA, et al. Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy. Mol Cancer Ther. 2008;7:944-951.
10.
Reis-Filho JS , Pinheiro C., Lambros MB, et al. EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. J Pathol. 2006;209:445-453.
Chan SK, Hill ME, Gullick WJThe role of the epidermal growth factor receptor in breast cancer. J Mammary Gland Biol Neoplasia. 2006;11:3-11.
13.
Lynch TJ, Bell DW, Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129-2139.
14.
Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497-1500.
15.
Bhargava R. , Gerald WL, Li AR, et al. EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol. 2005;18:1027-1033.
16.
Sauer T.Beraki K., Noren T., Garred O., Naess O.EGFR gene copy number heterogeneity in fine-needle aspiration cytology from breast carcinomas determined by chromogenic in situ hybridization. Diagn Cytopathol. 2005;33:228-232.
17.
Hirsch FR, Varella-Garcia M., McCoy J., et al. Increased epidermal growth receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioalveolar carcinoma subtypes: A Southwest Oncology Group Study. J Clin Oncol. 2005;23:6838-6845.
18.
Kapranos N. , Kounelis S., Karantasis H., Kouri E.Numerical aberrations of chromosomes 1 and 7 by fluorescent in situ hybridization and DNA ploidy analysis in breast cancer . Breast J. 2005;11:448-453.
19.
Sauer T., Beraki K., Jebsen PW, Ormerod E., Naess O.Ploidy analysis by in situ hybridization of interphase cell nuclei in fine-needle aspirates from breast carcinomas: correlation with cytologic grading. Diagn Cytopathol. 1997;17:267-271.
20.
Rákosy Z., Vízkeleti L., Ecsedi S., et al. EGFR gene copy number alterations in primary cutaneous malignant melanomas are associated with poor prognosis. Int J Cancer. 2007;121: 1729-1737.
21.
Buckley AF, Burgart LJ, Kakar S.Epidermal growth factor receptor expression and gene copy number in fibrolamellar hepatocellular carcinoma. Hum Pathol. 2006 ;37:410-414.
22.
Buckley AF, Burgart LJ, Sahai V., Kakar S.Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma. Am J Clin Pathol. 2008;129:245-251.
23.
Hirsch FR, Varella-Garcia M., Bunn PA Jr, et al. Epidermal growth factor receptor in non-small cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003;21:3798-3807.
24.
Hirsch FR, Varella-Garcia M., Cappuzzo F., et al. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol. 2007;18:752-760.
25.
Bigner SH, Wong AJ, Mark J., et al. Relationship between gene amplification and chromosomal deviations in malignant human gliomas. Cancer Genet Cytogenet. 1987;29: 165-170.
26.
Sauer T., Guren MG, Noren T., Dueland S.Demonstration of EGFR gene copy loss in colorectal carcinomas by fluorescence in situ hybridization (FISH): a surrogate marker for sensitivity to specific anti-EGFR therapy? Cancer Biol Ther. 2006;5:1494-1501.
27.
Schlomm T., Kirstein P., Iwers L., et al. Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer. Clin Cancer Res. 2007;15:6579-6584.
28.
Hirata K., Tagawa Y., Kashima K., et al. Frequency of chromosome 7 gain in human breast cancer cells: correlation with the number of metastatic lymph nodes and prognosis. Tohoku J Exp Med. 1998;184:85-97.
29.
Udart M., Utikal J., Kraehn GM, et al. Chromosome 7 aneusomy. A marker for metastatic melanoma? Expression of the epidermal growth factor receptor gene and chromosome 7 aneusomy in nevi, primary malignant melanomas and metastases. Neoplasia . 2001;3:245-254.
30.
Chung CH, Ely K., McGavran L., et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas . J Clin Oncol. 2006;24:4170-4176.
